K-PAX Pharmaceuticals is engaged in the development of products that support optimal mitochondrial metabolism.

K-PAX Pharmaceuticals is a San Francisco Bay Area biotech company. Our lead asset is KPAX002, a currently available drug that is bolstered by our proprietary mitochondrial technology. Combined with mitochondrial support, this drug now possesses the ability to effectively treat fatigue in patients with neurodegenerative diseases. We have completed several clinical trials demonstrating that KPAX002 has excellent safety and efficacy in several CNS disease states. 

We are currently pursuing several indications: 

1) Parkinson's disease non-motor symptoms

2) Alzheimer's disease cognitive symptoms

3) Myalgic encephalomyelitis/CFS